In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice

Executive Summary

Thermo Fisher’s $13.6 billion bid for Life Technologies is a blockbuster move within the instrumentation and consumables space, and also has implications for clinical practice. It’s another sign of the growing recognition that integrating clinical workflow is an important potential area for innovation and growth, along with the desire to move genomics tools into clinical use and the development of test content by nontraditional players in diagnostics.

You may also be interested in...



Next Steps For NuVasive Following CEO Resignation

The resignation of CEO Alex Lukianov could signal a shift in the spine firm's approach to sales and profitability that could ultimately make NuVasive as a more attractive acquisition candidate.

2013: The Year In Diagnostics

Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.

News Briefs: GE Healthcare Buys Thermo Fisher Research Tools; BD Acquires Alverix

GE Healthcare purchased Thermo Fisher’s research tools for $1 billion. Becton Dickinson acquires point-of-care diagnostic maker Alverix for $40 million. More news briefs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel